RAPP Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. (RAPP) is expected to report earnings on November 4, 2026, before the market open. The consensus earnings estimate is a loss of $1.21 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +14.5% since its last earnings release on August 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Rapport Therapeutics, Inc.
Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.
Sector
Healthcare
Industry
Biotechnology